Sun Yat-sen University: Sarcoma trials
The registry lists 16 Sarcoma studies with Sun Yat-sen University as lead sponsor. 6 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 11No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced SarcomaRecruitingNCT07648069Phase 1
- Cryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaRecruitingNCT07602049Phase 2
- Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety StudyRecruitingNCT06848582Not applicable
- Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT05952128Phase 2
- Adriamycin and Ifosfamide Combined With SintilimabRecruitingNCT04589754Phase 2
- Toripalimab Combined With CAV/IE RegimenRecruitingNCT04589741Phase 2
- Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue SarcomaStatus unknownNCT05778955
- Phase II Study of TAEST16001 in Soft Tissue SarcomaTerminatedNCT05549921Phase 2
- Surufatinib in Patients With Osteosarcoma and Soft Tissue SarcomaActive, not recruitingNCT05106777Phase 2
- Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue SarcomaStatus unknownNCT04606108Phase 2
- TAEST16001 in the Treatment of Soft Tissue SarcomaStatus unknownNCT04318964Phase 1
- Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaCompletedNCT04172805Phase 2
- Chidamide Combined With Toripalimab in SarcomaCompletedNCT04025931Phase 2
- Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue SarcomaStatus unknownNCT04012827Phase 2
- Anlotinib Maintenance Treatment for Advanced Soft Tissue SarcomaCompletedNCT03890068Phase 2
- NY-ESO-1-specific T Cell Receptor (TCR) T Cell in SarcomaCompletedNCT03462316Phase 1